Ranibizumab and bevacizumab for neovascular age-related macular degeneration
about
A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandardAflibercept for neovascular age-related macular degenerationAnti-vascular endothelial growth factor for control of wound healing in glaucoma surgeryAnti-vascular endothelial growth factor for diabetic macular oedemaAflibercept for neovascular age-related macular degenerationA Clearer View of Evidence in Treating Macular Degeneration: Off-Label Policies and Independent ResearchSystemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationAnti-vascular endothelial growth factor for neovascular age-related macular degenerationAnti-vascular endothelial growth factor for choroidal neovascularisation in people with pathologic myopiaSystemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationAnti-vascular endothelial growth factor for control of wound healing in glaucoma surgeryAntiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedemaSurgery for cataracts in people with age-related macular degenerationRanibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year resultsAssociation of Anti-VEGF Injections with Progression of Geographic AtrophyResistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive reviewRole of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trialsRegulation of signaling events involved in the pathophysiology of neovascular AMDInvolvement of B cells in non-infectious uveitisManagement of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled TrialsInflammation and its role in age-related macular degenerationAflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degenerationStereotactic radiotherapy for wet age-related macular degeneration: current perspectivesIndividualized Therapy with Ranibizumab in Wet Age-Related Macular DegenerationEffects of Vitreomacular Adhesion on Age-Related Macular DegenerationAnti-VEGF Therapy and the Retina: An UpdateTreatment of Exudative Age-related Macular Degeneration: Focus on AfliberceptTreatment as Required versus Regular Monthly Treatment in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-AnalysisIndividualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?Age-Related Macular Degeneration: Advances in Management and DiagnosisNLRP3 Inflammasome and Pathobiology in AMDCorneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in developmentOxygen sensing in retinal health and diseaseStem cells in retinal regeneration: past, present and futureThe rise of multiple imputation: a review of the reporting and implementation of the method in medical researchThe therapeutic potential of intraocular depot steroid systems: developments aimed at prolonging duration of efficacyComparative safety and tolerability of anti-VEGF therapy in age-related macular degenerationThe value of intraoperative optical coherence tomography imaging in vitreoretinal surgeryAdvances in drug delivery to the posterior segment
P2860
P800
Q21090878-BBA4240D-CBB2-4E9A-8288-A9F93CDFF276Q24186157-A5F28BE3-6686-4AED-8997-8C955D24C770Q24186464-D8791F74-2D47-4756-A3F6-124D3BDAA5BFQ24193083-8369D105-E439-4675-8BEF-0EF7816D3A4FQ24193255-03450257-03E9-4C57-835D-381A0B3DAA48Q24193409-33BC6257-0820-41AC-889E-CE259AD98BF2Q24193614-AAAB7391-8F2A-47B7-B6A4-8360472137FEQ24194251-7ED791A8-B454-4983-A0BC-FC32348D06DEQ24194332-06D12264-995D-4FBD-8237-3A41F708E60CQ24195003-4D9C6678-04F2-4268-A3C7-DABCC9AA00B1Q24200772-4F3C1246-58A4-49BC-A09E-B45618DBEC9CQ24202071-66486E4A-395A-4C97-91DD-1A8C8C8F79C4Q24202631-529ED27F-2C5B-492B-97AF-4515EC9B74A7Q24633874-ADC847BB-150A-43AB-AB41-91ED9CA4D2F7Q26741294-A08D1573-D904-4467-9D38-7BB438244696Q26744068-6891029B-24E1-4F57-9629-C7D9DD8D1310Q26750459-750C9421-F245-4370-A0BC-F3F31648A353Q26751293-75D74191-FC49-438F-A88B-C410E8E51AA4Q26766611-D327E1EA-DDBC-4364-8DE5-2ABF221A969CQ26767095-949C124F-A229-488F-8634-158D53349818Q26768520-600BA4A9-428A-4C8A-B1D3-D15912F6694AQ26771522-4F4CD35D-2CAF-441A-BCEE-262B054E1611Q26778521-EC5B4C3F-4A7C-42B9-B875-6A9F81A7C4FBQ26780543-BA32AE87-A2A9-4226-AB97-971006D25FD6Q26783389-56C7AE5F-0D80-4706-95D7-8D669E1271F8Q26784605-52B637C9-3EDA-42A6-BC35-34EDCD47B32CQ26786766-88A1896D-FC1F-490C-8492-C4137D04D1BEQ26787156-FDE374D5-EFC6-4C4F-B1BA-AD3615018D96Q26799492-063E8C08-CD19-49D9-9658-CAF3AF9157D6Q26799617-B1FF3C81-3F0E-4F46-8C72-72961A2EAC0BQ26799766-480EE63D-9717-4D62-BD62-8DD06EAB8BE4Q26823757-F66606E6-E721-407E-AA91-6ABED1BC0458Q26824335-127CFDB5-B316-4B04-A7E9-CDB395C7852FQ26827518-BC5C7B76-A3B2-42DC-918E-60A755E135DAQ26828014-F1B8117C-2273-4A1D-B9B7-FE0A876E6056Q26828889-DF1F1F5F-BC95-49EE-99CB-9ECCBB63B3FCQ26849299-A009EB3D-891E-4A57-AE5C-12CC8C27E984Q26852289-CA73A550-5EDA-4A08-BA01-16A9BCFFBF3FQ26864423-5A5E23A3-6CF9-43FC-8B83-32791F2BED20Q26995920-D789259E-21F2-407B-911F-E689C2B87278
P2860
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
@ast
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
@en
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
@nl
type
label
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
@ast
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
@en
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
@nl
prefLabel
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
@ast
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
@en
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
@nl
P2093
P2860
P3181
P356
P1476
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
@en
P2093
Daniel F Martin
Glenn J Jaffe
Gui-shuang Ying
Juan E Grunwald
Maureen G Maguire
Stuart L Fine
P2860
P304
P3181
P356
10.1056/NEJMOA1102673
P407
P50
P577
2011-05-19T00:00:00Z